CompaniesActavis

Actavis

defunct

About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (100)

View all

Total Trials

100

As Lead Sponsor

As Collaborator

Total Enrollment

25,251

By Phase

PHASE1: 67PHASE3: 29NA: 2PHASE4: 2

By Status

COMPLETED: 95TERMINATED: 2WITHDRAWN: 2ACTIVE_NOT_RECRUITING: 1

Clinical Trials Pipeline100 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

2042

2043

2044

Today

NCT00864305

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 1997

Completion: Jan 31, 1998

NCT00864058

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 31, 1998

Completion: Jan 31, 1998

NCT00864760

A Relative Bioavailability Study of Gabapentin 800 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 1999

Completion: Jun 30, 1999

NCT00865631

A Limited Food Effect Study of Gabapentin 800 mg Tablets

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 1999

Completion: Jun 30, 1999

NCT00865059

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2001

Completion: Mar 31, 2001

NCT00865423

A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2001

Completion: Mar 31, 2001

NCT00865384

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2001

Completion: Sep 30, 2001

NCT00865696

A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2001

Completion: Sep 30, 2001

NCT00864669

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2002

Completion: Mar 31, 2002

NCT00865839

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2002

Completion: Mar 31, 2002

NCT00864734

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2002

Completion: Nov 30, 2002

NCT00865241

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2002

Completion: Nov 30, 2002

NCT00864565

A Relative Bioavailability Study of Fentanyl 25 μg/h Transdermal System

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2003

Completion: Jun 30, 2003

NCT00864890

A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2003

Completion: Jul 31, 2003

NCT00865085

A Relative Bioavailability Study of Citalopram 40 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2003

Completion: Jul 31, 2003

NCT00865943

A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2003

Completion: Aug 31, 2003

NCT00865072

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2003

Completion: Aug 31, 2003

NCT00865852

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2003

Completion: Aug 31, 2003

NCT00865267

The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2003

Completion: Dec 31, 2003

NCT00865605

Pivotal Bioequivalence Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2003

Completion: Jul 31, 2004

NCT00865748

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 31, 2004

Completion: Jan 31, 2004

NCT00865436

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2004

Completion: Apr 30, 2004

NCT00782548

Comparative Study to Evaluate KADIAN and Avinza in Healthy Adults

Phase: Phase 4

Role: Lead Sponsor

Start: May 31, 2004

Completion: Jun 30, 2004

NCT00863941

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2004

Completion: Jul 31, 2004

NCT00865462

A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2004

Completion: Jul 31, 2004

NCT00759356

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2004

Completion: Sep 30, 2004

NCT00864019

A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2004

Completion: Aug 31, 2004

NCT00864344

A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2004

Completion: Aug 31, 2004

NCT00865410

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2004

Completion: Sep 30, 2004

NCT00759759

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2004

Completion: Oct 31, 2004

NCT00759954

Comparison of One Morphine Sulfate Sustained-Release 200 mg Capsule With Two 100 mg KADIAN Capsules on Applesauce

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2004

Completion: Oct 31, 2004

NCT00864162

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2004

Completion: Oct 31, 2004

NCT00865371

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2004

Completion: Sep 30, 2004

NCT00863915

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2004

Completion: Oct 31, 2004

NCT00864448

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2004

Completion: Oct 31, 2004

NCT00870480

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2004

Completion: Nov 30, 2004

NCT00871247

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2004

Completion: Nov 30, 2004

NCT01190748

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2004

Completion: Dec 31, 2004

NCT01190761

Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2004

Completion: Dec 31, 2004

NCT00865215

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2005

Completion: Apr 30, 2005

NCT00870142

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2005

Completion: May 31, 2005

NCT00870571

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2005

Completion: May 31, 2005

NCT00864617

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2005

Completion: May 31, 2005

NCT00864747

A Relative Bioavailability Study of Propranolol HCl 160 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2005

Completion: May 31, 2005

NCT00865891

A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2005

Completion: Jul 31, 2005

NCT00865657

A Relative Bioavailability Study of Alprazolam 3 mg Extended Release Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2005

Completion: Sep 30, 2005

NCT00865761

A Relative Bioavailability Study of Alprazolam 3 mg ER Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Sep 30, 2005

Completion: Sep 30, 2005

NCT00864149

A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2005

Completion: Nov 30, 2005

NCT00864240

"The Dose-response Pilot Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects"

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2005

Completion: Oct 31, 2005

NCT00864435

A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2005

Completion: Nov 30, 2005

NCT00864071

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2005

Completion: Nov 30, 2005

NCT00864500

Pivotal Bioequivalence Study of Topically Delivered Clobetasol Propionate Lotion in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2005

Completion: Feb 28, 2006

NCT00863863

A Relative Bioavailability Study of Griseofulvin 125 mg/5 mL Suspension Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 31, 2006

Completion: Jan 31, 2006

NCT00865111

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2006

Completion: Apr 30, 2006

NCT00871364

A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2006

Completion: May 31, 2006

NCT00768183

Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2006

Completion: Jul 31, 2006

NCT01188031

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2006

Completion: Jul 31, 2006

NCT01188057

A Relative Bioavailability Study of 2 mg Alprazolam OD Tablets Under Non-Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2006

Completion: Aug 31, 2006

NCT00759902

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2006

Completion: Oct 31, 2006

NCT00759915

Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2006

Completion: Oct 31, 2006

NCT00863902

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2006

Completion: Sep 30, 2006

NCT00864279

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 31, 2006

Completion: Sep 30, 2006

NCT00864357

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Non-fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2006

Completion: Oct 31, 2006

NCT00864526

A Relative Bioavailability Study of Oxycodone 5 mg / Ibuprofen 400 mg Tablets Under Fasting Conditions

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2006

Completion: Oct 31, 2006

NCT00864968

Single Dose Two-Way Crossover Fasted Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2007

Completion: Mar 31, 2007

NCT00864604

Single Dose Two-Way Crossover Fed Bioequivalence Study of Nabumetone 750 mg Tablets in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2007

Completion: May 31, 2007

NCT00948428

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2008

Completion: Apr 30, 2009

NCT01760980

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2012

Completion: Dec 31, 2014

NCT01850823

Clinical Equivalence Study of Mometasone Nasal Spray

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 28, 2013

Completion: Dec 31, 2013

NCT01962987

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2013

Completion: Sep 30, 2013

NCT01901146

Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer

Phase: Phase 3

Role: Collaborator

Start: Apr 29, 2013

Completion: Jan 27, 2017

NCT02120924

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2013

Completion: Sep 30, 2014

NCT02120898

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 10, 2013

Completion: Apr 30, 2014

NCT01966003

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Phase: Phase 3

Role: Collaborator

Start: Nov 11, 2013

Completion: Jul 23, 2015

NCT02210689

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2014

Completion: Dec 31, 2014

NCT02324270

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2014

Completion: Dec 31, 2014

NCT02267746

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2014

Completion: Sep 30, 2014

NCT02289352

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2014

Completion: Dec 31, 2014

NCT02616601

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 27, 2015

Completion: Sep 17, 2015

NCT02654769

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 28, 2015

Completion: Sep 30, 2015

NCT02791308

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Phase: Phase 3

Role: Lead Sponsor

Start: Feb 28, 2015

Completion: Jul 31, 2016

NCT02512042

Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2015

Completion: May 31, 2016

NCT02616614

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2015

Completion: Nov 30, 2015

NCT02475369

Pancreatic Enzyme Supplementation for Celiac Disease

Phase: Phase 4

Role: Collaborator

Start: May 31, 2015

Completion: Dec 31, 2019

NCT02495857

A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee

Phase: N/A

Role: Lead Sponsor

Start: Aug 15, 2015

Completion: Dec 5, 2016

NCT02496715

Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics

Phase: Phase 3

Role: Lead Sponsor

Start: Sep 30, 2015

Completion: Dec 31, 2016

NCT02651220

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 30, 2015

Completion: Oct 31, 2016

NCT02498418

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 6, 2016

Completion: Feb 28, 2017

NCT03294538

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

Phase: Phase 3

Role: Lead Sponsor

Start: May 18, 2016

Completion: Feb 15, 2017

NCT02840461

Clinical Endpoint Study of Ivermectin 1% Cream

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 30, 2016

Completion: Dec 31, 2016

NCT03287791

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 19, 2016

Completion: Jun 22, 2017

NCT03200912

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

Phase: Phase 3

Role: Lead Sponsor

Start: Aug 19, 2016

Completion: Mar 22, 2017

NCT02495168

Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 13, 2017

Completion: May 31, 2018

NCT03301649

Clinical Endpoint Study of Ivermectin 0.5% Lotion

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 7, 2017

Completion: Mar 12, 2018

NCT03499873

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 28, 2018

Completion: Dec 18, 2018

NCT03756883

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

Phase: Phase 3

Role: Lead Sponsor

Start: Dec 3, 2018

Completion: Nov 10, 2019

NCT03852706

EEG-based Neurofeedback for Auditory Verbal Hallucinations (HALFEED)

Phase: N/A

Role: Collaborator

Start: Mar 1, 2019

Completion: Mar 25, 2022

NCT03879837

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 25, 2019

Completion: Jul 9, 2021

NCT03954444

"A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream"

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 15, 2019

Completion: Feb 27, 2020

NCT05577000

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

Phase: Phase 1

Role: Collaborator

Start: Oct 18, 2021

Completion: Oct 1, 2043

NCT05577000

Hover over trial bars to see details

Recent Trials

NCT05577000Collaborator

Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

PHASE1Active, not recruiting

5 participants

Started: Oct 18, 2021 · Completed: Oct 1, 2043

NCT03954444Lead Sponsor

"A Clinical Endpoint Bioequivalence Study of Oxymetazoline Hydrochloride Cream"

PHASE3Completed

1,105 participants

Started: Apr 15, 2019 · Completed: Feb 27, 2020

NCT03879837Lead Sponsor

Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

PHASE3Completed

1,902 participants

Started: Mar 25, 2019 · Completed: Jul 9, 2021

NCT03852706Collaborator

EEG-based Neurofeedback for Auditory Verbal Hallucinations (HALFEED)

NATerminated

4 participants

Started: Mar 1, 2019 · Completed: Mar 25, 2022

NCT03756883Lead Sponsor

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

PHASE3Completed

999 participants

Started: Dec 3, 2018 · Completed: Nov 10, 2019

View all 100 trials →